GleamWall
中文EN

ANTX AN2 Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1880438 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.5%
TTM EPS YoY19.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-51.3%
ROA-46.7%
ROIC (approx.)-60.6%
Asset turnover—

Leverage & solvency

Liabilities / assets7.9%
Debt / equity0.00x
Current ratio10.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.72M$6.02M$6.74M$6.88M$7.00M$3.20M$7.69M$5.40M
SG&A expense$2.95M$2.88M$3.81M$2.44M$3.04M$4.02M$3.85M$3.21M
Operating income-$8.67M-$8.90M-$10.55M-$9.32M-$10.04M-$7.22M-$11.54M-$8.60M
Net income-$7.96M-$8.19M-$10.03M-$8.67M-$9.35M-$6.46M-$10.65M-$7.52M
EPS (basic)-0.17-0.18-0.29—-0.31-0.21-0.35—
EPS (diluted)-0.17-0.18-0.29—-0.31-0.21-0.35—
Weighted avg. shares (diluted)46.11M44.76M34.06M—30.28M30.17M30.05M—
Balance sheet
Cash & equivalents$20.21M$44.32M$53.49M$19.94M$18.00M$18.22M$19.98M$21.35M
Short-term investments$44.19M$34.07M$31.80M$38.06M$43.92M$44.70M$47.08M$62.27M
Current assets$65.76M$79.99M$87.49M$59.94M$64.02M$67.52M$69.56M$86.26M
Total assets$81.95M$81.68M$87.49M$61.95M$67.23M$75.83M$81.34M$92.09M
Current liabilities$6.28M$5.58M$5.56M$8.72M———$10.24M
Total liabilities$6.45M$5.75M$5.73M$8.89M$6.86M$6.98M$8.01M$10.24M
Shareholders' equity$75.51M$75.92M$81.76M$53.06M$60.38M$68.84M$73.33M$81.85M
Shares outstanding37.89M36.31M35.99M27.41M27.37M27.38M30.14M29.92M
Cash flow statement
Operating cash flow-$6.10M-$7.00M-$12.07M-$5.24M-$6.38M-$7.60M-$10.62M-$5.27M
Investing cash flow-$24.44M-$3.66M$8.29M$7.17M$6.11M$5.83M$9.19M-$6.88M
Financing cash flow$6.43M$1.49M$37.33M$0$48,000$0$65,000$0
Stock-based compensation$973,000$972,000$1.46M$1.40M$801,000$2.00M$2.05M$1.78M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.